Transcranial alternating current stimulation (tACS) is rapidly emerging as a groundbreaking neuromodulation technique poised to transform the treatment landscape of neuropsychiatric disorders. Unlike more traditional brain stimulation approaches, such as transcranial direct current stimulation (tDCS), tACS administers sinusoidal, biphasic alternating currents at specific, finely tuned frequencies—an innovation that allows for unprecedented precision in modulating neural oscillatory activity. This frequency-targeted approach not only enhances the specificity of neuromodulation but also significantly reduces the sensory side effects that have historically limited patient compliance with such interventions. As researchers delve deeper into the biophysical mechanisms underlying tACS, a crescendo of clinical and translational findings signals its potential to revolutionize therapies for disorders ranging from depression to Parkinson’s disease.
At the core of tACS’s therapeutic efficacy lies its ability to entrain and normalize aberrant brain oscillations across a spectrum of frequency bands. Theta (4–8 Hz), alpha (8–13 Hz), beta (13–30 Hz), and gamma (30–100 Hz) rhythms represent foundational neuronal activities implicated in cognition, emotion, and sensorimotor integration. By targeting these oscillations, tACS rebalances dysfunctional neural circuitries—essential for restoring circuit-level homeostasis in patients afflicted by neuropsychiatric pathologies. For instance, theta-band modulation dynamically influences memory encoding and emotional regulation, while alpha rhythms are integral to attentional focus and anxiety management. Beta and gamma bands, linked respectively to motor control and higher cognitive functions, can be finely tuned to bolster working memory, executive functions, and perceptual accuracy, thus underscoring the broad neuroscience substrate tACS can engage.
Beyond modulation of oscillatory patterns, tACS facilitates long-lasting synaptic plasticity through mechanisms such as spike-timing-dependent plasticity (STDP). This mechanism exploits precise temporal alignment between neuronal spiking and externally applied electric fields, thereby inducing long-term potentiation (LTP) or depression (LTD). The involvement of NMDA receptor-mediated pathways further consolidates these synaptic changes, conferring durable improvements in neural network efficiency and adaptability. As a result, tACS does not merely produce transient effects but can engender sustained neurophysiological reorganization, a crucial attribute for enduring symptom remission in chronic disorders.
The neuromodulatory capacity of tACS also extends to the regulation of neurotransmitter systems. Experimental data reveal modulation of serotonin, norepinephrine, dopamine, and β-endorphin release, neurochemicals that orchestrate mood, arousal, pain perception, and cognitive flexibility. Such biochemical shifts complement electrophysiological effects, collectively contributing to the normalization of brain states disrupted in psychiatric and neurological diseases. This multifaceted influence situates tACS at the interface of electrophysiology and neurochemistry, offering a comprehensive framework for intervention that transcends simplistic stimulation paradigms.
From a network perspective, tACS enhances functional connectivity between key brain regions implicated in cognition and emotion, notably strengthening the coupling between the prefrontal cortex and limbic system. Additionally, it affects structural connectivity by modulating white matter integrity, likely via activity-dependent myelin plasticity. These network-level refinements are paramount for re-establishing communication pathways that are frequently compromised in disorders such as schizophrenia and Alzheimer’s disease, promoting integrated brain function.
In clinical landscapes, tACS has demonstrated remarkable promise across a spectrum of neuropsychiatric disorders. For treatment-resistant major depressive disorder (MDD), applying 77.5 Hz tACS to the prefrontal cortex coupled with bilateral mastoid stimulation at intensities up to 15 milliamperes (mA) engenders robust antidepressant effects. These effects are particularly marked with twice-daily sessions and are potentiated by concurrent low-dose escitalopram, which synergistically modulates frontal alpha power. This combination illustrates how tACS can be integrated with pharmacotherapy to optimize outcomes.
Schizophrenia, characterized by complex symptoms including cognitive deficits and hallucinations, also responds to targeted tACS interventions. Gamma frequency stimulation directed at the dorsolateral prefrontal cortex alleviates negative symptoms and cognitive impairments, while alpha frequency tACS targeting the temporoparietal junction reduces auditory hallucinations. Theta tACS further enhances working memory and attentional capacities, illuminating the frequency-specific therapeutic windows of tACS tailored to symptom clusters.
Obsessive-compulsive disorder (OCD) patients benefit from personalized high-definition tACS across beta-gamma spectra over the orbitofrontal cortex. This protocol yields profound symptom reduction lasting up to three months, linked mechanistically to increased local neuronal activity and decreased dopaminergic signaling, highlighting the nuanced neurochemical underpinnings of tACS therapeutic actions.
In the realm of neurodegeneration, tACS has emerged as a novel intervention for Alzheimer’s disease. Gamma-frequency (40 Hz) stimulation not only augments episodic memory but also reinforces functional connectivity between the default mode network and hippocampus—regions notoriously impaired during disease progression. Intriguingly, lack of responsiveness to gamma tACS may serve as an early biomarker for imminent conversion from mild cognitive impairment to overt dementia, opening avenues for early diagnosis and personalized intervention.
Parkinson’s disease management experiences a potential breakthrough with individualized tACS protocols derived from each patient’s electroencephalography (EEG) signatures. These tailored stimulations ameliorate motor symptoms such as tremor and bradykinesia and enhance cognitive function, reflecting the adaptability of tACS to heterogeneous neurological phenotypes.
Stroke rehabilitation harnesses tACS through novel applications such as gait-synchronized stimulation paired with neuromuscular electrical therapy, dramatically improving motor recovery and walking speed. Additionally, theta-frequency tACS combined with speech therapy significantly boosts language recovery in post-stroke aphasia, exemplifying the versatility of tACS in neurorehabilitation.
Non-motor symptoms such as chronic insomnia and migraine have also shown favorable responses to 77.5 Hz tACS protocols. Improved sleep quality and extended duration in elderly populations, along with reductions in migraine attack frequency and severity via enhanced β-endorphin and serotonin release, reflect tACS’s broad therapeutic reach beyond classical psychiatric domains.
Achieving therapeutic efficacy with tACS hinges on meticulous optimization of key parameters including frequency, intensity, phase alignment, duration, and session frequency. Deeper brain regions like the hippocampus and amygdala require higher intensities, sometimes reaching 15 mA, to ensure adequate electric field penetration—a feat achieved without compromising safety. Precision targeting, informed by functional neuroimaging or high-density EEG, ensures stimulation directly addresses pathological oscillations rather than generalized brain regions.
Individual patient factors, encompassing age, illness stage, brain morphology, and baseline neural dynamics mandate personalized stimulation regimens. Advanced closed-loop systems employing real-time EEG monitoring enable adaptive parameter adjustments, maximizing efficacy while minimizing side effects. This replicates naturalistic brain-state-dependent modulation, elevating tACS beyond static paradigms towards truly dynamic neuromodulation.
Despite remarkable advances, significant obstacles constrain widespread clinical integration of tACS. Current knowledge largely derives from small cohorts, single-center trials, and preliminary case reports, underscoring the pressing need for large-scale, multicenter, randomized controlled trials with double-blind designs. These studies are critical to establish standardized protocols, elucidate long-term safety profiles, and validate reproducibility across diverse populations.
Technical limitations remain a formidable challenge, particularly concerning spatial resolution and effective depth targeting. Emerging technologies like temporal interference stimulation offer promising solutions by enabling noninvasive modulation of deep brain structures with greater focality and minimized off-target effects, potentially overcoming key roadblocks inherent to conventional tACS.
Future trajectories for tACS research envision the dawn of precision medicine paradigms, integrating intelligent closed-loop neuromodulation platforms with cutting-edge neuroimaging techniques and machine learning algorithms. Such systems will adapt stimulation parameters in real-time, tailored to dynamic neural states, maximizing therapeutic gains while minimizing risks.
The convergence of neuroscience, bioengineering, clinical disciplines, and computational sciences is critical in harnessing the full potential of tACS. This interdisciplinary synergy promises continued technological innovation, fostering robust scientific validation and establishing tACS as a cornerstone of personalized neuropsychiatric treatment.
As this field matures, tACS stands poised to transcend experimental boundaries and emerge as a transformative noninvasive brain stimulation modality. Through rigorous clinical trials, technological refinement, and personalized application, it holds the promise to significantly reshape outcomes for millions afflicted by neuropsychiatric disorders worldwide.
Subject of Research: Not applicable
Article Title: Mechanisms and clinical applications of transcranial alternating current stimulation in the treatment of neuropsychiatric disorders: Current evidence and future directions
News Publication Date: 5-Apr-2026
Web References: http://dx.doi.org/10.1097/CM9.0000000000004012
References: DOI: 10.1097/CM9.0000000000004012
Image Credits: Hongxing Wang from Capital Medical University, China
Keywords: Depression, Psychological science, Clinical psychology, Psychiatric disorders, Affective disorders, Life sciences, Organismal biology, Nervous system, Central nervous system, Brain, Diseases and disorders, Neurological disorders, Neurodegenerative diseases, Alzheimer disease
